AI Insight: Collegium Pharmaceutical trades significantly below its PERT-weighted fair value of $299.47, indicating substantial upside potential. Monte Carlo analysis shows extreme volatility but zero downside scenarios under the current price, reflecting low immediate downside risk. Strong profitability (5/5) contrasts with weak growth (1/5) and leverage (1/5), suggesting operational strength amid growth concerns.